By Fineline Cube 
Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from China’s Ministry of Ecology and Environment (MEE) for its radionuclide drug conjugate (RDC) megafactory in Chengdu, which cost RMB 3 billion (USD 416 million). The facility is expected to commence full operations in June 2024.
Facility Highlights
Positioned as the world’s first closed-loop platform for the entire RDC industry chain, the factory will focus on isotope process development, nuclear drug coupling technology, and automated labeling technology. It will provide one-stop full lifecycle management covering nuclear drug research and development, production, and distribution.
Technical and Operational Advantages
The plant features 14 production lines compliant with Good Manufacturing Practice (GMP) and is equipped with a full-chain AI operation system and intelligent manufacturing system. This enables independent manufacturing of various isotopes and nuclear drug preparations, with a dedicated alpha nuclide drug production line reserved. Currently, it stands as one of the most comprehensive and automated intelligent factories in the international arena for nuclide types.-Fineline Info & Tech